Skip to main content

Table 1 Baseline characteristics according to the sorafenib response

From: Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study

Variable All (n = 124) Non-PD (n = 44) PD (n = 80) P
Age (year) 61 ± 11 62 ± 10 61 ± 12 0.707
Sex, N (%) 107 (86.3) 36 (81.8) 71 (88.8) 0.423
ECOG performance status 0, N (%) 112 (90.3) 42 (95.5) 70 (87.5) 0.210
Etiology, N (%)     0.02
 HBV 91 (73.4) 26 (59.1) 65 (81.2)  
 HCV 21 (16.9) 10 (22.7) 11 (13.8)  
 Alcohol 12 (9.7) 8 (18.2) 4 (5)  
Body mass index (kg/m2) 22.3 ± 3.1 23.1 ± 3.2 21.9 ± 3.0 0.052
Macrovascular invasion, N (%) 39 (31.5) 11 (25.0) 28 (35.0) 0.344
Extrahepatic spread, N (%) 53 (42.7%) 16 (36.4) 37 (46.2) 0.382
BCLC stage C, N (%) 83 (66.9%) 25 (56.8) 58 (72.5) 0.185
Child-Pugh score, N (%)     0.492
 5 114 (91.9) 42 (95.5) 72 (90)  
 6 10 (8.1) 2 (4.5) 8 (10)  
MELD 8.8 ± 2.2 8.36 ± 1.54 8.96 ± 2.47 0.1
Albumin (g/dL) 3.79 ± 0.42 3.78 ± 0.46 3.81 ± 0.41 0.739
Total bilirubin (mg/dL) 1.06 ± 0.50 0.99 ± 0.47 1.09 ± 0.51 0.273
Prothrombin time (INR) 1.14 ± 0.10 1.13 ± 0.09 1.15 ± 0.1 0.299
Creatinine (mg/dL) 0.89 ± 0.56 0.87 ± 0.13 0.9 ± 0.69 0.705
Platelet (×103/μL) 122 (17–787) 113 (17–291) 128 (52–787) 0.006
Alpha-fetoprotein (ng/mL) 128.8 (1.3–730,000) 114.7 (2.6–226,100) 152.2 (1.3–730,000) 0.187
PIVKA-II (mAU/mL) 109.5 (12–339,858) 25.5 (12–25,884) 351 (15–339,858) 0.003
Angiopoietin 2 (ng/mL) 2962.7 (1099.4–12,907.8) 2762.2 (1289.6–8360.4) 3026.9 (1099.4–12,907.8) 0.109
CD117 (ng/mL) 3.76 (1.01–226.85) 3.36 (1.01–10.23) 3.87 (1.10–226.85) 0.234
bFGF (pg/mL) 2.38 (0–61.57) 1.65 (0–14.62) 3.07 (0.43–61.57) < 0.001
HGF (pg/mL) 1781.9 (913.9–6116.0) 1605.7 (913.9–4152.4) 1965.2 (1020.3–6117.0) 0.056
LOXL2 (ng/mL) 0.816 (0.034–4.007) 0.718 (0.034–4.007) 0.850 (0.039–3.765) 0.792
PDGFRb (pg/mL) 2045.6 (647.5–22,904.5) 2087.9 (777.7–22,904.5) 1965.3 (647.5–8214.9) 0.419
sVEGFR1 (ng/mL) 0.16 (0.04–13.65) 0.16 (0.06–13.65) 0.14 (0.04–0.53) 0.314
AAR 1.29 (0.58–11.6) 1.31 (0.58–2.67) 1.29 (0.61–11.6) 0.105
APRI 1.01 (0.17–6.54) 1.17 (0.17–4.54) 0.95 (0.17–6.54) 0.847
FIB-4 4.0 (0.6–21.0) 4.4 (0.9–21.0) 3.6 (0.6–12.3) 0.161
Lok index 0.66 ± 0.24 0.67 ± 0.24 0.65 ± 0.24 0.68
P2/MS 29.6 (0.46–1060.7) 27.3 (0.5–202.4) 36.7 (6.2–1060.7) 0.102
  1. Values are expressed as mean ± standard deviation, medians (ranges), or frequencies (percentages)
  2. Abbreviations: PD, progressive disease, ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, MELD model for end-stage liver disease, INR international normalized ratio, PIVKA-II protein induced by vitamin K absence-II, Ang2 angiopoietin-2, bFGF basic fibroblast growth factor, HGF hepatocyte growth factor, LOXL2 lysyl oxidase-like 2, PDGFRb platelet-derived growth factor receptor β, sVEGFR1 soluble vascular endothelial growth factor receptor-1, AAR aspartate aminotransferase/alanine aminotransferase ratio, APRI aspartate aminotransferase to platelet ratio index, FIB-4 fibrosis 4